A Phase IB Study of TTI-621 and TTI-622 in Combination with Daratumumab Hyaluronidase-fihj in People with Multiple Myeloma

Share

Full Title

A Phase Ib Study Of The Combination Of CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-622) And Daratumumab Hyaluronidase-fihj For Patients With Relapsed or Refractory Multiple Myeloma

Purpose

The purpose of this study is to find the highest doses of the investigational drugs TTI-621 and TTI-622 that can be given in combination with daratumumab hyaluronidase-fihj in people with multiple myeloma that has come back or continued to grow despite treatment. TTI-621 and TTI-622 each work by helping the immune system find and kill cancer cells.

Patients in this study will receive either TTI-621 or TTI-622 (but not both) in combination with daratumumab hyaluronidase-fihj. TTI-621 and TTI-622 are given intravenously (by vein). Daratumumab hyaluronidase-fihj is given as an injection subcutaneously (under the skin).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have multiple myeloma that persists despite at least three prior regimens of therapy.
  • Patients should recover from the serious side effects of previous treatments before receiving the study treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

 

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Alexander Lesokhin at 646-608-3717.

Protocol

21-122

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators